Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02066298 · ClinicalTrials.gov registry record · Phase 3

Steroids In Eosinophil Negative Asthma

A Phase 3 study, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
Phase 3
Development phase
295
Enrollment target

NCT02066298 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 295 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02066298, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
295 participants
Enrollment target

Study Summary

Because approximately half of all mild-moderately-severe asthma is persistently non-eosinophilic, it is important to determine prospectively if patients who are persistently non-eosinophilic differ in their benefit from inhaled corticosteroid treatment compared to patients who are not persistently non-eosinophilic.

Interventions

  • DRUG Placebo
  • DRUG Mometasone 220mcg BID
  • DRUG Tiotropium Respimat 5mcg QD

Trial Details

FieldValue
Enrollment Target 295 participants
Start Date 2014-07
Est. Completion 2018-05
Phase Phase 3

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT02066298

The ClinicalTrials.gov registry entry for NCT02066298 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02066298 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02066298 about?

NCT02066298 is a clinical study titled "Steroids In Eosinophil Negative Asthma". Because approximately half of all mild-moderately-severe asthma is persistently non-eosinophilic, it is important to determine prospectively if patients who are persistently non-eosinophilic differ in their benefit from inhaled corticosteroid treatment compared to patients who are not persistently n...

What is the current status of trial NCT02066298?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 295 participants. The study started on 2014-07. Estimated completion is 2018-05.

What interventions are being tested in trial NCT02066298?

The interventions under investigation include: Placebo (DRUG), Mometasone 220mcg BID (DRUG), Tiotropium Respimat 5mcg QD (DRUG).

Who is sponsoring clinical trial NCT02066298?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.